In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
News|Podcasts|September 3, 2026
ACT Brief: Human Readiness as Operational Foundation, Early Phase Capacity Consolidation, and AI-Driven Patient Matching Scale
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why many trial failures trace to human readiness gaps rather than process design alone, how CRO consolidation expands early-phase capacity, and how AI-enabled patient matching is reshaping recruitment economics.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the
pilot episode of The Human Side of Clinical Trials , Brian McGowan, PhD, chief learning officer and co-founder of ArcheMedX, introduced a framework showing why operational failures in trials often trace to gaps in human readiness rather than process design. When enrollment falls behind, protocol deviations increase, or sites struggle after activation, organizations must ask whether people were adequately prepared and equipped with genuine understanding, not just information. Fortrea announced the acquisition of Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in all-cash, adding a 200-bed clinical pharmacology unit, a bioanalytical laboratory, and biospecimen storage in Texas. The combination reduces handoffs between clinical and bioanalytical functions, improves turnaround times, and enables sponsors to run larger studies with greater operational flexibility.- In a
new contributed article , Partha Anbil and Anamika Krishanpal examined how 80% to 85% of trials miss enrollment timelines with trial delays costing $600,000 to $800,000 per day in lost revenue. AI-enabled patient matching and EHR integration are becoming operational levers, but bias, explainability, and governance will determine whether the technology scales across diverse patient populations.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
4
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
5